Acumen Pharmaceuticals, Inc. (ABOS) shareholders
Close on Nov 17, 2026Market cap $16.64MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (29.50%), Rajeev Shah (29.50%) and 1 more | 21,101,669 | 29.50% | 13D (active) amendment | Mar 13, 2026 |
| James B. Murray Jr. | 3,611,360 | 5.00% | 13G (passive) | Apr 4, 2025 |
| Sands Capital Alternatives, LLC Joint filing with Sands Frank M. (5.60%) | 3,417,075 | 5.60% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABOS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 20,992,669 | 29.02% | $56.05M | – | 0.49% |
| Sands Capital Ventures, LLC | 3,720,105 | 5.14% | $9.93M | – | 1.62% |
| BlackRock, Inc. | 2,490,115 | 3.44% | $6.65M | +2,311,789 | 0.00% |
| Alyeska Investment Group, L.P. | 2,454,754 | 3.39% | $6.55M | – | 0.02% |
| Franklin Resources Inc | 2,305,096 | 3.19% | $6.15M | – | 0.00% |
| ADAR1 Capital Management, LLC | 2,111,334 | 2.92% | $5.64M | −45,000 | 0.26% |
| Vanguard Capital Management LLC | 1,672,072 | 2.31% | $4.46M | +165,795 | 0.00% |
| Knollwood Investment Advisory, LLC | 1,628,510 | 2.25% | $4.35M | – | 0.39% |
| Geode Capital Management, LLC | 1,141,858 | 1.58% | $3.05M | +725,620 | 0.00% |
| Ikarian Capital, LLC | 1,053,797 | 1.46% | $2.81M | – | 0.30% |
| Hudson Bay Capital Management LP | 955,000 | 1.32% | $2.55M | −13,940 | 0.01% |
| Pathstone Holdings, LLC | 859,110 | 1.19% | $2.29M | – | 0.01% |
| Renaissance Technologies LLC | 675,025 | 0.93% | $1.80M | +201,079 | 0.00% |
| Two Sigma Investments, LP | 622,882 | 0.86% | $1.66M | +92,070 | 0.00% |
| State Street Corp | 600,528 | 0.83% | $1.60M | +448,800 | 0.00% |
| Northern Trust Corp | 360,744 | 0.50% | $963.19K | +285,532 | 0.00% |
| Vanguard Portfolio Management LLC | 320,795 | 0.44% | $856.52K | New | 0.00% |
| Dimensional Fund Advisors LP | 291,559 | 0.40% | $778.97K | +171,803 | 0.00% |
| Vanguard Fiduciary Trust Co | 291,240 | 0.40% | $777.61K | +92,014 | 0.00% |
| Bank Of America Corp /De/ | 274,781 | 0.38% | $733.67K | −45,435 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 48M | 66.2% | 30 / 21 | 15 / 17 | 6M | 4M |
| Q1 2026 | 84 | 46M | 63.6% | 21 / 31 | 12 / 7 | 14M | 2M |
| Q4 2025 | 71 | 36M | 49.3% | 12 / 13 | 22 / 8 | 1M | 1M |
| Q3 2025 | 69 | 36M | 49.4% | 13 / 8 | 28 / 15 | 2M | 4M |
| Q2 2025 | 71 | 38M | 52.0% | 17 / 15 | 22 / 27 | 3M | 5M |
| Q1 2025 | 81 | 40M | 55.7% | 11 / 15 | 33 / 9 | 1M | 3M |
| Q4 2024 | 80 | 43M | 58.8% | 16 / 28 | 19 / 8 | 2M | 3M |
| Q3 2024 | 73 | 44M | 60.4% | 11 / 24 | 21 / 17 | 4M | 1M |
| Q2 2024 | 81 | 44M | 60.3% | 23 / 21 | 20 / 22 | 5M | 5M |
| Q1 2024 | 80 | 44M | 60.2% | 24 / 22 | 24 / 11 | 7M | 1M |
| Q4 2023 | 67 | 38M | 53.2% | 20 / 27 | 10 / 18 | 4M | 9M |
| Q3 2023 | 66 | 44M | 60.4% | 25 / 23 | 11 / 12 | 20M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
56 funds held ABOS in Q2 2026, 63% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ABOS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,118,322 | 1.55% | $2.99M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,036,119 | 1.43% | $2.77M | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 826,400 | 1.14% | $1.78M | 0.15% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 513,773 | 0.71% | $1.10M | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 513,511 | 0.71% | $1.37M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 430,091 | 0.59% | $1.15M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 177,191 | 0.24% | $460.70K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 158,629 | 0.22% | $423.54K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 115,088 | 0.16% | $247.44K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 100,013 | 0.14% | $215.03K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 88,342 | 0.12% | $235.87K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 87,871 | 0.12% | $234.62K | 0.16% | Jun 30, 2026 |
| Ultra-Small Company Fund | 75,000 | 0.10% | $200.25K | 0.20% | Jun 30, 2026 |
| Fidelity Small Cap Value Index Fund | 65,832 | 0.09% | $175.77K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 63,355 | 0.09% | $136.21K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel Joseph OConnell | Chief Executive Officer, Director | 881,275 | 1.22% | Jan 23, 2026 |
| Derek M. Meisner | Chief Legal Officer & Corp Sec | 173,999 | 0.24% | Mar 10, 2026 |
| Eric Siemers | Chief Medical Officer | 255,371 | 0.35% | Jan 23, 2026 |
| Russell Barton | Chief Operating Officer | 205,092 | 0.28% | Jan 23, 2026 |
| Matt Zuga | CFO & Chief Business Officer | 304,924 | 0.42% | Jan 23, 2026 |
| James J. Doherty | President and CDO | 220,900 | 0.31% | Jan 21, 2026 |
| Amy Schacterle | Chief Regulatory Officer | 92,303 | 0.13% | Jan 21, 2026 |
| Derrell Porter | Director | 48,540 | 0.07% | Jun 17, 2026 |
| Nathan B. Fountain | Director | 48,150 | 0.07% | Jun 10, 2026 |
| Kimberlee C. Drapkin | Director | 48,300 | 0.07% | Jun 5, 2026 |
| John A. Stalfort III | Director | 352,219 | 0.49% | Jun 5, 2026 |
| Rajeev M. Shah | Director, 10% owner | 19,103,785 | 26.41% | Jun 5, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | – | Jun 5, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 13,043,179 | 18.03% | Jun 5, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | 48,300 | 0.07% | Jun 5, 2026 |
| Laura Stoppel | Director | 48,300 | 0.07% | Jun 5, 2026 |
| George Golumbeski | Director | 35,500 | 0.05% | Jun 5, 2026 |
| Jeffrey L. Ives | Director | 48,300 | 0.07% | Jun 5, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 12,800 | 0.02% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Derrell Porter Director | Jun 17, 2026 | Option exercise | +13,040 | $1.07 | $13.95K | 48,540 |
| Derrell Porter Director | Jun 17, 2026 | Sale | −13,040 | $2.33 | $30.38K | 35,500 |
| Derrell Porter Director | Jun 16, 2026 | Sale | −12,800 | $2.33 | $29.82K | 35,500 |
| Derrell Porter Director | Jun 15, 2026 | Sale | −6,460 | $2.35 | $15.18K | 48,300 |
| Derrell Porter Director | Jun 15, 2026 | Option exercise | +6,460 | $1.07 | $6.91K | 54,760 |
| Nathan B. Fountain Director | Jun 9, 2026 | Sale | −6,400 | $2.23 | $14.27K | 48,150 |
| Jeffrey L. Ives Director | Jun 3, 2026 | Award | +35,500 | – | – | 48,300 |
| Nathan B. Fountain Director | Jun 3, 2026 | Award | +35,500 | – | – | 54,550 |
| John A. Stalfort III Director | Jun 3, 2026 | Award | +35,500 | – | – | 220,624 |
| RA Capital Nexus Fund II, L.P. Director | Jun 3, 2026 | Award | +35,500 | – | – | 48,300 |
| Laura Stoppel Director | Jun 3, 2026 | Award | +35,500 | – | – | 48,300 |
| Derrell Porter Director | Jun 3, 2026 | Award | +35,500 | – | – | 48,300 |
| George Golumbeski Director | Jun 3, 2026 | Award | +35,500 | – | – | 35,500 |
| Kimberlee C. Drapkin Director | Jun 3, 2026 | Award | +35,500 | – | – | 48,300 |
| Rajeev M. Shah Director, 10% owner | Mar 16, 2026 | Award | +6,060,606 | $3.30 | $20.00M | 19,103,785 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Mar 6, 2026 | Sale(10b5-1 plan) | −2,090 | $3.26 | $6.81K | 173,999 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Mar 6, 2026 | Option exercise | +2,090 | $1.85 | $3.87K | 176,089 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Feb 27, 2026 | Sale(10b5-1 plan) | −9,406 | $3.01 | $28.31K | 173,999 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Feb 27, 2026 | Option exercise | +9,406 | $1.85 | $17.40K | 183,405 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 28, 2026 | Sale(10b5-1 plan) | −2,671 | $3.00 | $8.01K | 173,999 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 28, 2026 | Option exercise | +2,671 | $1.85 | $4.94K | 176,670 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 26, 2026 | Option exercise | +15,085 | $1.85 | $27.91K | 189,084 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 26, 2026 | Sale(10b5-1 plan) | −15,085 | $3.00 | $45.26K | 173,999 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 23, 2026 | Sale(10b5-1 plan) | −5,633 | $1.90 | $10.70K | 173,999 |
| Eric Siemers Chief Medical Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −895 | $1.82 | $1.63K | 255,371 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 22, 2026 | Sale(10b5-1 plan) | −1,054 | $1.84 | $1.94K | 179,632 |
| Matt Zuga CFO & Chief Business Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −1,687 | $1.86 | $3.14K | 304,924 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 22, 2026 | Sale(10b5-1 plan) | −2,689 | $1.88 | $5.06K | 881,275 |
| Russell Barton Chief Operating Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −462 | $1.84 | $850 | 205,092 |
| Eric Siemers Chief Medical Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −2,331 | $1.80 | $4.20K | 256,266 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 21, 2026 | Sale(10b5-1 plan) | −2,247 | $1.81 | $4.07K | 180,686 |
| Matt Zuga CFO & Chief Business Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −2,473 | $1.81 | $4.48K | 306,611 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 21, 2026 | Sale(10b5-1 plan) | −9,346 | $1.81 | $16.92K | 883,964 |
| Russell Barton Chief Operating Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −2,315 | $1.81 | $4.19K | 205,554 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 20, 2026 | Award | +299,800 | – | – | 893,310 |
| James J. Doherty President and CDO | Jan 16, 2026 | Award | +166,867 | – | – | 220,900 |
| Russell Barton Chief Operating Officer | Jan 16, 2026 | Award | +84,600 | – | – | 207,869 |
| Amy Schacterle Chief Regulatory Officer | Jan 16, 2026 | Award | +84,600 | – | – | 92,303 |
| Eric Siemers Chief Medical Officer | Jan 16, 2026 | Award | +99,133 | – | – | 258,597 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 16, 2026 | Award | +99,133 | – | – | 182,933 |
| Matt Zuga CFO & Chief Business Officer | Jan 16, 2026 | Award | +99,133 | – | – | 309,084 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 12, 2026 | Sale(10b5-1 plan) | −5,388 | $1.73 | $9.32K | 593,510 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 12, 2026 | Sale(10b5-1 plan) | −8,548 | $1.71 | $14.62K | 83,800 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 9, 2026 | Sale(10b5-1 plan) | −12,941 | $1.76 | $22.78K | 598,898 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 9, 2026 | Sale(10b5-1 plan) | −5,200 | $1.76 | $9.15K | 92,348 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 8, 2026 | Sale(10b5-1 plan) | −8,143 | $1.82 | $14.82K | 611,839 |
| Russell Barton Chief Operating Officer | Jan 8, 2026 | Sale(10b5-1 plan) | −3,530 | $1.86 | $6.57K | 123,269 |
| Matt Zuga CFO & Chief Business Officer | Jan 8, 2026 | Sale(10b5-1 plan) | −6,888 | $1.82 | $12.54K | 209,951 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 8, 2026 | Sale(10b5-1 plan) | −6,819 | $1.82 | $12.41K | 127,640 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 8, 2026 | Sale(10b5-1 plan) | −30,092 | $1.82 | $54.77K | 97,548 |
| James J. Doherty President and CDO | Jan 8, 2026 | Sale(10b5-1 plan) | −6,467 | $1.82 | $11.77K | 54,033 |
| James J. Doherty President and CDO | Jan 7, 2026 | Sale(10b5-1 plan) | −1,700 | $1.99 | $3.38K | 60,500 |
| Amy Schacterle Chief Regulatory Officer | Jan 7, 2026 | Sale(10b5-1 plan) | −1,097 | $1.98 | $2.17K | 7,703 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −37,755 | $1.99 | $75.13K | 619,982 |
| Matt Zuga CFO & Chief Business Officer | Jan 7, 2026 | Sale(10b5-1 plan) | −1,700 | $1.99 | $3.38K | 216,839 |
| Matt Zuga CFO & Chief Business Officer | Jan 7, 2026 | Sale(10b5-1 plan) | −4,105 | $2.00 | $8.21K | 218,539 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 7, 2026 | Sale(10b5-1 plan) | −1,700 | $1.99 | $3.38K | 144,529 |
| Derek M. Meisner Chief Legal Officer & Corp Sec | Jan 7, 2026 | Sale(10b5-1 plan) | −10,070 | $1.99 | $20.04K | 134,459 |
| Russell Barton Chief Operating Officer | Jan 7, 2026 | Sale(10b5-1 plan) | −1,700 | $1.99 | $3.38K | 126,799 |
| Daniel Joseph OConnell Chief Executive Officer, Director | Jan 6, 2026 | Sale(10b5-1 plan) | −5,102 | $1.97 | $10.05K | 657,737 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Acumen Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,347 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Derrell Porter Director | Jun 17, 2026 | 13,040 | $30.32K | Jun 17, 2026 | Stock Option Exercise |
| Derrell Porter Director | Jun 16, 2026 | 12,800 | $29.77K | Jun 16, 2026 | Restricted Stock |
| Derrell Porter Director | Jun 15, 2026 | 6,460 | $15.15K | Jun 15, 2026 | Stock Option Exercise |
| Nathan B. Fountain Director | Jun 9, 2026 | 6,400 | $14.27K | Jun 9, 2026 | Restricted Stock |
| Derek M. Meisner Officer | Mar 6, 2026 | 2,090 | $6.73K | Mar 6, 2026 | Exercise of employee stock options |
| Derek M. Meisner Officer | Feb 27, 2026 | 9,406 | $28.31K | Feb 27, 2026 | Exercise of employee stock options |
| Derek M. Meisner Officer | Jan 28, 2026 | 2,671 | $8.02K | Jan 28, 2026 | Exercise of employee stock options |
| Derek M. Meisner Officer | Jan 26, 2026 | 15,085 | $45.26K | Jan 27, 2026 | Exercise of employee stock options |
| Derek M. Meisner Officer | Jan 23, 2026 | 5,633 | $10.49K | Jan 23, 2026 | Vesting of restricted stock unit award |
| Daniel Joseph OConnell Officer, Director | Jan 22, 2026 | 2,689 | $5.07K | Jan 22, 2026 | Vesting of restricted stock unit award |
| Eric Siemers Officer | Jan 22, 2026 | 895 | $1.63K | Jan 22, 2026 | Vesting of restricted stock unit award |
| Russell Barton Officer | Jan 22, 2026 | 462 | $850 | Jan 22, 2026 | Vesting of restricted stock unit award |
| Derek M. Meisner Officer | Jan 22, 2026 | 1,054 | $1.94K | Jan 22, 2026 | Vesting of restricted stock unit award |
| Matt Zuga Officer | Jan 22, 2026 | 1,687 | $3.14K | Jan 22, 2026 | Vesting of restricted stock unit award |
| Derek M. Meisner Officer | Jan 21, 2026 | 2,247 | $4.06K | Jan 21, 2026 | Vesting of restricted stock unit award |
See a number that looks wrong?